This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-001319-mlkaowqr | The immune response to severe bacterial infections: consequences for therapy Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure IgM in microbial infections: taken for granted? |
| cord-018284-grvj99eh | Early goal- directed therapy in the treatment of severe sepsis and septic shock Drug therapy: Management of sepsis Vasopressin versus norepinephrine infusion in patients with septic shock Effects of hydroxyethyl starch and gelatine on renal function in severe sepsis: a multicentre randomised study Blutkulturdiagnostik Sepsis, Endokarditis, Katheterinfektionen, Teil 1 Deutscher Anästhesiecongress Pro& Contra- Sitzung: » Selensubstitution bei Sepsis? |
| cord-030385-btf502ju | Biomarkers of sepsis Two decades of mortality trends among patients with severe sepsis: a comparative meta- analysis Incidence and trends of sepsis in US hospitals using clinical vs claims data Biomarker cruises in sepsis: who is the CAPTAIN? |
| cord-030385-btf502ju | catabolism syndrome Penkid: a novel biomarker of reduced GFR in sepsis Adaptation of a biomarker- based sepsis mortality risk stratification tool for pediatric acute respiratory distress syndrome Reconsidering lactate as a sepsis risk biomarker Gender differences in sepsis: genetically determined? |
| cord-006414-60lpjg09 | Bd 18 Is low monocyte HLA- DR expression helpful to predict outcome in severe sepsis? |
| cord-006414-60lpjg09 | therapeutischer Ansatz? |
| cord-302379-jh6jxwyn | Is conservative treatment of deep neck space infections appropriate? |
| cord-001293-dfaxj3bv | Are patients with sepsis dying of immune failure-dissecting the arguments used to describe compensatory immunosuppression occurring after sepsis? |
| cord-001293-dfaxj3bv | Is boosting the immune system in sepsis appropriate? |
| cord-001293-dfaxj3bv | authors: Cavaillon, Jean- Marc; Eisen, Damon; Annane, Djilalli title: Is boosting the immune system in sepsis appropriate? |
| cord-017420-tjwxec77 | Meta- analysis of randomized controlled trials of prophylactic granulocyte colony- stimulating factor and granulocyte- macrophage colony- stimulating factor after autologous and allogeneic stem cell transplantation Blood platelets and sepsis pathophysiology: a new therapeutic prospect in critical ill patients? |
| cord-297039-vfuem6bk | How are circRNAs translated by non- canonical initiation mechanisms? |
| cord-016127-tbot0fc9 | Analysis of incidence, outcome, and associated cost of care Is the mortality rate for septic shock really decreasing? |
| cord-016127-tbot0fc9 | Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration? |
| cord-270213-ygb64yxc | do we stand? |
| cord-005872-w1x1i0im | Does elevated nitric oxide production enhance the release of prostacyclin from shear stressed aortic endothelial cells? |
| cord-005872-w1x1i0im | To block or enhance its production during sepsis? |
| cord-017337-vq3edhxn | New method of classifying infections in critically ill patients Septic shock of early or late onset: does it matter? |
| cord-017337-vq3edhxn | The Key to Success? |
| cord-347833-b3yrxkt0 | The third international consensus definitions for sepsis and septic shock( sepsis-3) Does infection- induced immune activation contribute to dementia? |
| cord-347833-b3yrxkt0 | What do we know about quality of life in dementia? |
| cord-017376-wrhkfcff | Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms Does promoting resolution instead of inhibiting inflammation represent the new paradigm in treating infections? |
| cord-017376-wrhkfcff | Why have clinical trials in sepsis failed? |
| cord-017376-wrhkfcff | authors: Liu, Yongjian; Hao, Yu; Bhandari, Suwas; Jin, Shengwei title: Pro- resolution of Inflammation: New Hints to Manage Sepsis? |
| cord-017376-wrhkfcff | current estimates and limitations Is sepsis a pro- resolution deficiency disorder? |
| cord-023935-o2ffxgnn | In monitoring her response to these interventions, which of the following should NOT be used as a therapeutic endpoint to monitor her progress? |
| cord-023935-o2ffxgnn | There is suffi cient data to justify the use of which of the following adjuvant therapies in pediatric sepsis? |
| cord-023935-o2ffxgnn | Which of the following components of coagulation is increased during sepsis? |
| cord-005697-l1zmrq4p | Future implications: immuno- adjuvants to the rescue? |
| cord-005697-l1zmrq4p | How should development of immunosuppression impact clinical management? |
| cord-005697-l1zmrq4p | Pène, Frédéric; Pickkers, Peter; Hotchkiss, Richard S. title: Is this critically ill patient immunocompromised? |
| cord-005697-l1zmrq4p | Time for a paradigm change? |
| cord-006426-baf2d47y | Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression Toll- like receptor signalling on Tregs: to suppress or not to suppress? |
| cord-006426-baf2d47y | Marker of injury or mediator of infl ammation? |
| cord-006426-baf2d47y | Systemic cytokine response after major surgery Chemokines: extracellular messengers for all occasions? |
| cord-006426-baf2d47y | The"danger"sensors that STOP the immune response: the A2 adenosine receptors? |
| cord-348785-f67amppy | A systematic analysis for the Global Burden of Disease Study Does leflunomide attenuate the sepsis- induced acute lung injury? |
| cord-348785-f67amppy | Biochemical basis of ozone toxicity A novel animal model of sepsis after acute lung injury in sheep Ozone therapy and hyperbaric oxygen treatment in lung injury in Septic rats Has mortality from acute respiratory distress syndrome decreased over time? |
| cord-348785-f67amppy | Does ozone therapy normalize the cellular redox balance? |
| cord-348785-f67amppy | Has ozone therapy a future in medicine? |
| cord-298505-r7ihqb96 | Bacterial viruses against viruses pathogenic for man? |
| cord-298505-r7ihqb96 | It was first detected in Wuhan, China, which suggests the existence of an intermediary( pangolin?) |
| cord-298505-r7ihqb96 | Virus Res T4 bacteriophagemediated inhibition of adsorption and replication of human adenovirus in vitro Bacteriophage uptake by eukaryotic cell layers represents a major sink for phagesduring therapy Inhibitory effects of bacteriophage preparations on adenoviral replication Phages in the fight against COVID-19? |
| cord-312197-d5d8amk7 | Evidencebased, cost- effective interventions: how many newborn babies can we save? |
| cord-312197-d5d8amk7 | Oral antibiotics in the management of serious neonatal bacterial infections in developing country communities Management of newborn infections in primary care settings: a review of the evidence and implications for policy? |
| cord-312197-d5d8amk7 | Where? |
| cord-312197-d5d8amk7 | Why? |
| cord-312197-d5d8amk7 | when? |
| cord-252859-zir02q69 | Can gene or protein expression profiles be used to diagnose sepsis in other animal models? |
| cord-252859-zir02q69 | If so, are there predictive gene sets that are common to different types of infection( eg, gram- positive versus gram- negative infections)? |
| cord-252859-zir02q69 | Once the diagnosis has been made, are there markers that indicate response to therapy or prognosis? |
| cord-252859-zir02q69 | What are the optimal computational methods to identify robust predictors from microarray or proteomic data? |
| cord-005497-w81ysjf9 | ( 1) Are serum- S1P levels affected by cardiac surgery? |
| cord-005497-w81ysjf9 | ( 2) Are potential alterations of serum- S1P levels related to changes of acute- phase proteins, S1P sources or carrier? |
| cord-005497-w81ysjf9 | ( 3) Is the invasiveness of the surgery a factor that may influence serum- S1P levels? |
| cord-005497-w81ysjf9 | A hybrid approach as treatment for coronary artery disease: endo- CABG or PCI first, does it matter? |
| cord-005497-w81ysjf9 | Assessing the volume of blood taken for blood culture and culture positivitydo we need to take less blood? |
| cord-005497-w81ysjf9 | Does the endotoxin adsorption of PMX column saturate in 2 hours? |
| cord-005497-w81ysjf9 | What is the useful coagulation and fibrinolysis marker for predicting extracorporeal membrane oxygenation circuit exchange due to intra- circuit thrombus? |
| cord-104180-f3hoz9bu | Can we manipulate this therapeutically in human sepsis? |
| cord-104180-f3hoz9bu | Recently published papers: inflammation, elucidation, manipulation? |
| cord-104180-f3hoz9bu | So will stress doses of hydrocortisone attenuate severe systemic inflammatory response syndrome after cardiac surgery with cardiopulmonary bypass? |
| cord-104180-f3hoz9bu | Why is this so? |
| cord-104180-f3hoz9bu | With respect to inotropes, which one should we use? |
| cord-104180-f3hoz9bu | a prospective clinical trial Adrenocortical hormones in survivors and nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehydroepiandrosterone- sulfate, and cortisol Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery Coagulation blockade prevents sepsis- induced respiratory and renal failure in baboons Blockade of tissue factor: treatment for organ injury in established sepsis Development of ionized hypomagnesemia is associated with higher mortality rates Injurious mechanical ventilation and end- organ epithelial cell apoptosis and organ dysfunction in an experi- Critical Care Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial Prevention of endotracheal suctioning- induced alveolar derecruitment in acute lung injury Dose- response characteristics during long- term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? |
| cord-017470-sjk7a34u | But who is the conductor? |
| cord-017470-sjk7a34u | Pulmonary edema Is the mortality higher in the pulmonary vs the extrapulmonary ARDS? |
| cord-017470-sjk7a34u | The lingering consequences of sepsis: the hidden public health disaster? |
| cord-017470-sjk7a34u | a systematic review Glucocorticoids potently block tumor necrosis factor- alpha and lipopolysaccharide- induced apoptotic cell death in bovine glomerular endothelial cells upstream of caspase 3 activation Renal blood flow distribution in experimental septic acute renal failure Pathophysiology of septic acute kidney injury: what do we really know? |
| cord-017470-sjk7a34u | following a brief exposure to endotoxin: a mechanism to link infection and infarction? |
| cord-017470-sjk7a34u | paradigms lost? |
| cord-000522-d498qj2b | Can drotrecogin alfa( activated) be used in patients on dialysis for pre- existing renal failure, a category that was specifically excluded in the PROWESS trial? |
| cord-000522-d498qj2b | Do patients require any laboratory testing before they receive drotrecogin alfa( activated)? |
| cord-000522-d498qj2b | How do severe sepsis and septic shock differ hemodynamically in the early stages compared with that classically described in the ICU? |
| cord-000522-d498qj2b | What are the most important ways in which EGDT can improve outcomes? |
| cord-000522-d498qj2b | What is the optimal dose for this intervention? |
| cord-000522-d498qj2b | What is the optimal duration for this intervention? |
| cord-000522-d498qj2b | Why was cardiovascular collapse a significant cause of death in the control group? |
| cord-302295-nblmshni | Approaching the asymptote? |
| cord-302295-nblmshni | How important are Toll- like receptors for antimicrobial responses? |
| cord-302295-nblmshni | Sepsis studies need new direction Recombinant human activated protein C as a therapy for severe sepsis: lessons learned? |
| cord-302295-nblmshni | So, how to explore more efficiently new treatment strategies? |
| cord-302295-nblmshni | Targeting Toll- like receptors: emerging therapeutics? |
| cord-302295-nblmshni | The search for effective therapy for sepsis: back to the drawing board? |
| cord-018840-ts2g1ux7 | A new paradigm for the treatment of sepsis: is it time to consider combination therapy? |
| cord-018840-ts2g1ux7 | A study of the American Bone Marrow Transplant Group Does intravenous immune globulin have a role in HIV- infected patients? |
| cord-018840-ts2g1ux7 | CCM.0000216189.80613.BB Mirror, mirror on the wall, which is the fairest meta- analysis of all? |
| cord-018840-ts2g1ux7 | The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review Comparison of early IgM- enriched immunoglobulin vs polyvalent IgG administration in score- identified postcardiac surgical patients at high risk for sepsis Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation Haemolytic anaemia after lung transplantation: an immune- mediated phenomenon Intravenous immunoglobulin therapy: how does IgG modulate the immune system? |
| cord-018840-ts2g1ux7 | Why have clinical trials in sepsis failed? |
| cord-018840-ts2g1ux7 | a pediatric oncology group study Afelimomab- another therapeutic option in sepsis therapy? |
| cord-018840-ts2g1ux7 | how to choose the best option for the patient? |
| cord-018840-ts2g1ux7 | the answer"no"? |
| cord-015024-2xzc0uc5 | Does chest physical therapy work? |
| cord-015024-2xzc0uc5 | IN TERMS OF IMPROVING LUNG FUNCTION? |
| cord-015024-2xzc0uc5 | Intraoperative fluid restriction improves outcome after major elective gastrointestinal surgery SURROGATE DESIGNATION: CAN WE TRUST OUR RELATIVES? |
| cord-015024-2xzc0uc5 | The development and evaluation of an incident reporting system in intensive care Adverse events in critical ill patients Ministry of Health and Social Policy 1254 COMMUNICATION: A KEY FACTOR IN THE PATIENT SAFETY? |
| cord-015024-2xzc0uc5 | There was however a clear decrease in serum ferritin levels from 162 ± 48 at baseline to 109? |
| cord-015024-2xzc0uc5 | To the staff of the critical care department, faculty of medicine Injury severity and quality of life: whose perspective is important? |
| cord-015024-2xzc0uc5 | sodium bicarbonatein treting lactic acidosis from shock? |
| cord-005569-9d51l6bn | ( 2) What ICP technologies are available and what are their relative advantages/ disadvantages? |
| cord-005569-9d51l6bn | ( 3) Should CPP monitoring and autoregulation testing be used? |
| cord-005569-9d51l6bn | ( 5) Should structurally normal or abnormal tissue be monitored with PbrO(2)? |
| cord-005569-9d51l6bn | ( 6) Should microdialysis be considered in complex cases? |
| cord-005569-9d51l6bn | An assessment of the validity of spectral entropy as a measure of sedation state in mechanically ventilated critically ill patients Understanding international differences in terminology for delirium and other types of acute brain dysfunction in critically ill patients Recognition and labeling of delirium symptoms by intensivists: does it matter? |
| cord-005569-9d51l6bn | Hyponatremia in neurological patients: cerebral salt wasting versus inappropriate antidiuretic hormone secretion Is procalcitonin a marker of critical illness in heatstroke? |
| cord-005569-9d51l6bn | Median PCT value was 0.58 lg/ l and 31( 58%) patients had PCT above 0.2 lg/ l( PCT?). |
| cord-005569-9d51l6bn | Once is not enough: clinical trials in sepsis Influence of insertion site on central venous catheter colonization and bloodstream infection rates Indwelling time and risk of colonization of peripheral arterial catheters in critically ill patients Risk factors and prognosis of catheter- related bloodstream infection in critically ill patients: a multicenter study Do antibiotics administered at the time of central venous catheter removal interfere with the evaluation of colonization? |
| cord-005569-9d51l6bn | Preoperative apolipoprotein CI levels correlate positively with the proinflammatory response in patients experiencing endotoxemia following elective cardiac surgery Gene profiling in human blood leucocytes during recovery from septic shock Sepsis mortality prediction based on predisposition, infection and response Prognostic value of midregional pro- atrial natriuretic peptide in ventilator- associated pneumonia Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis Stress doses of hydrocortisone in septic shock: beneficial effects on opsonizationdependent neutrophil functions Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? |
| cord-005569-9d51l6bn | The effects of sedation on gastric emptying and intra- gastric meal distribution in critical illness Initial efficacy and tolerability of early enteral nutrition with immediate or gradual introduction in intubated patients Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin- based prokinetic therapy for feed intolerance Immunonutrition in critically ill patients: a systematic review and analysis of the literature Fish oil supplementation in the parenteral nutrition of critically ill medical patients: a randomised controlled trial Antiinflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock Serum levels of osteopontin are increased in SIRS and sepsis Does severe non- infectious SIRS differ from severe sepsis? |
| cord-005569-9d51l6bn | The first was, what is the current probability that activated protein C is not better than the control? |
| cord-005569-9d51l6bn | The questions discussed and addressed in this manuscript were:( 1) Who should have ICP monitoring and for how long? |
| cord-005569-9d51l6bn | When should brain tissue oxygen tension[ PbrO(2)] be monitored? |
| cord-005569-9d51l6bn | and, if the current probability is not small, then the second question was, how many patients will be needed for the activated protein C confirmatory trial? |
| cord-005569-9d51l6bn | are we getting out of the black hole in sepsis research? |
| cord-349076-x3rjasg0 | ("Who?"), the questions of"When?"and"How much?"remain open. |
| cord-349076-x3rjasg0 | ("Who?"), the questions of"When?"and"How much?"remain open. |
| cord-349076-x3rjasg0 | ("Who?"), the questions of"When?"and"How much?"remain open. |
| cord-349076-x3rjasg0 | ,"When?"and"How Much?" |
| cord-349076-x3rjasg0 | ,"When?"and"How Much?" |
| cord-349076-x3rjasg0 | : Double- edged swords of innate immunity Age is the work of art? |
| cord-349076-x3rjasg0 | Can Concurrent Abnormalities in Free Light Chains and Immunoglobulin Concentrations Identify a Target Population for Immunoglobulin Trials in Sepsis? |
| cord-349076-x3rjasg0 | Can immune therapies reduce mortality? |
| cord-349076-x3rjasg0 | How are T(H)2-type immune responses initiated and amplified? |
| cord-349076-x3rjasg0 | The Questions of"Who?" |
| cord-349076-x3rjasg0 | Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? |
| cord-349076-x3rjasg0 | Why have clinical trials in sepsis failed? |
| cord-349076-x3rjasg0 | an effective adjuvant in septic VLBW infants? |
| cord-020643-0yzkqykg | A controlled trial of dichloroacetate for treatment of lactic acidosis in adults Der Darm als immunologisches Organ Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome Plasma exchange as rescue therapy in multiple organ failure ncluding acute renal failure Treatment strategies for acute myocardial infarction complicated by cardiogenic shock in a community hospital Enterale Immunonutrition: wann, für wen, welche Zukunftsperspektiven gibt es? |
| cord-020643-0yzkqykg | Bestandteil des Multiorganversagens in der Sepsis? |
| cord-020643-0yzkqykg | Dysfunktion seiner Patienten Beachtung schenken? |
| cord-020643-0yzkqykg | Endemie- Erfassung der Ostalbregion und Literaturübersicht Hemodynamic and metabolic effects of low- dose vasopressin infusions in vasodilatory septic shock Inhibition of 38 mitogen activated protein kinase: a novel strategy in sepsis? |
| cord-020643-0yzkqykg | One- year outcomes in survivors of the acute respiratory distress syndrome Does immunonutrition in patients with sepsis do more harm than good? |
| cord-020643-0yzkqykg | Patienten? |
| cord-020643-0yzkqykg | Should we emergently revascularize occluded coronaries for cardiogenic shock? |
| cord-020643-0yzkqykg | Should we emergently revascularize occluded coronaries for cardiogenic shock? |
| cord-020643-0yzkqykg | Sind diese in der Diagnostik nutzbar? |
| cord-020643-0yzkqykg | Ursachen oder Folgen? |
| cord-020643-0yzkqykg | an acute myocardial infarction Organ apoptosis in the septic patient: A potential therapeutic target? |
| cord-020643-0yzkqykg | ein Nierenversagen? |
| cord-020643-0yzkqykg | sind MODS- anfällig? |
| cord-020643-0yzkqykg | systemic infl ammatory response syndrome Cytokines, nitrite/ nitrate, soluble tumor factor receptors, and procalcitonin concentations: Comparison in patients with septic shock, cardiogenic shock, and bacterial pneumonia Coronary hemodynamics and myocardial metabolism in sepsis and septic shock Kristalloide versus Kolloide-A never ending story? |
| cord-022592-g7rmzsv5 | : a multicentre study Are complete blood cell counts useful in the evaluation of asymptomatic neonates exposed to suspected chorioamnionitis? |
| cord-022592-g7rmzsv5 | Can expression of CD45RO, a T- cell surface molecule, be used to detect congenital infection? |
| cord-022592-g7rmzsv5 | Can neutrophil responses in very low birth weight infants predict the organisms responsible for late- onset bacterial or fungal sepsis? |
| cord-022592-g7rmzsv5 | Does IVIg administration yield improved immune function in very premature neonates? |
| cord-022592-g7rmzsv5 | Echocardiogram done early in neonatal sepsis: what does it add? |
| cord-022592-g7rmzsv5 | Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach Prevention of lymphocyte apoptosisa potential treatment of sepsis? |
| cord-022592-g7rmzsv5 | Increased CD4+ T cell co- inhibitory immune receptor CEACAM1 in neonatal sepsis and soluble- CEACAM1 in meningococcal sepsis: a role in sepsis- associated immune suppression? |
| cord-022592-g7rmzsv5 | New synthetic surfactants: the next generation? |
| cord-022592-g7rmzsv5 | The expression of surface tissue factor apoprotein by blood monocytes in the course of infections in early infancy Complement and coagulation: strangers or partners in crime? |
| cord-022592-g7rmzsv5 | The platelet hyporeactivity of extremely low birth weight neonates is age- dependent The Ashwell receptor mitigates the lethal coagulopathy of sepsis Platelet count and sepsis in very low birth weight neonates: is there an organism- specific response? |
| cord-022592-g7rmzsv5 | Where? |
| cord-022592-g7rmzsv5 | Where? |
| cord-022592-g7rmzsv5 | Which inotrope for which baby? |
| cord-022592-g7rmzsv5 | Why have clinical trials in sepsis failed? |
| cord-022592-g7rmzsv5 | Why? |
| cord-022592-g7rmzsv5 | Why? |
| cord-022592-g7rmzsv5 | when? |
| cord-022592-g7rmzsv5 | when? |
| cord-006460-3ayc0hne | -20 years later The complications of trauma and their associated costs in a level I trauma center Are we winning the battle in the surgical intensive care unit? |
| cord-006460-3ayc0hne | 8 primes neutrophils in patients with trauma at risk of multiple organ failure Does programmed cell death( apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? |
| cord-006460-3ayc0hne | An acronym or a response? |
| cord-006460-3ayc0hne | Are these the causes or are they associations that are not totally worked out? |
| cord-006460-3ayc0hne | Are we improving patient care and, if so, how? |
| cord-006460-3ayc0hne | Are we improving patient care, are we winning the battle[ 96, 97], and is MOF disappearing? |
| cord-006460-3ayc0hne | Blakiston's Gould medical dictionary SIRS, MODS, MOFwhat's in a name? |
| cord-006460-3ayc0hne | Can we control inflammation without doing harm to the host? |
| cord-006460-3ayc0hne | Does H. pylori modulate the response to injury and is it a nosocomial infection[ 83, 84]? |
| cord-006460-3ayc0hne | Have there been any clinical advances in the care of patients in the past 20 years? |
| cord-006460-3ayc0hne | Helicobacter pylori and critical illness: a passive bystander or cause of disease? |
| cord-006460-3ayc0hne | How do we sort out which is most important and which should be treated or blocked? |
| cord-006460-3ayc0hne | Is there an interleukin-1 genetic predisposition to developing severe sepsis? |
| cord-006460-3ayc0hne | Is there immune deficiency or immune excess? |
| cord-006460-3ayc0hne | They can only be documented by the types of experience that were cited earlier in the section entitled"Are we improving patient care and, if so, how?: |
| cord-006460-3ayc0hne | Thus, to answer the question-is MOF disappearing? |
| cord-006460-3ayc0hne | What difference does it make? |
| cord-006460-3ayc0hne | What is the answer to this gender gap? |
| cord-006460-3ayc0hne | What should you do if you are injured and develop an infection? |
| cord-006460-3ayc0hne | What's in a name? |
| cord-006460-3ayc0hne | Why have new effective therapies for sepsis not been developed? |
| cord-006460-3ayc0hne | Why have there been failures of so many potential magic bullets? |
| cord-006460-3ayc0hne | Why is this? |
| cord-006460-3ayc0hne | Why sepsis trials fail Anti- inflammatory therapies to treat sepsis and septic shock: a reassessment MOF, MODS and SIRS-why no magic bullets? |
| cord-006460-3ayc0hne | do we stand Multiple organ failure: is it disappearing? |
| cord-006460-3ayc0hne | growth hormone, glutamine, and a modified diet Characterization of growth hormone enhanced donor site healing in patients with large cutaneous burns Priming of the neutrophil respiratory burst is species- dependent and involves MAP kinase activation Molecular mimicry and autoimmunity Systemic inflammatory response syndrome( SIRS), multiple organ dysfunction syndrome( MODS), multiple organ failure( MOF): are we winning the battle? |
| cord-006460-3ayc0hne | it disappearing? |
| cord-006460-3ayc0hne | old ideas crushed, new mysteries bared Inflammation, infection, and coronary artery disease Does Chlamydia pneumoniae cause atherosclerosis? |
| cord-006460-3ayc0hne | we winning the battle? |
| cord-015021-pol2qm74 | ( 3) Should future clinical trials be based on new classifications of illness such as MODS, SIRS, APACHE III, SAP II, MRM, etc., or should trials be dedicated to specific diseases-urinary tract infections, pneumonia, trauma patients, cardiac surgery and other specific problems, rather than generalized problems of sepsis, the sepsis syndrome and other classifications? |
| cord-015021-pol2qm74 | 3-Is the ACCP classification of sepsis useful at the bedside to select oatients? |
| cord-015021-pol2qm74 | Abnormally high skeletal muscle pO 2 in septic patients and its normalization during recovery: Evidence against tissue hypoxia but for impaired oxygen metabolism of skeletal muscle? |
| cord-015021-pol2qm74 | Administration of exogenous IFN? |
| cord-015021-pol2qm74 | And, finally, how can the participants be sure that the trial will be stopped at the right time, to ensure that no treatment is given to any patient that might be harmful? |
| cord-015021-pol2qm74 | Are all eligible patients being studied, and their results reported? |
| cord-015021-pol2qm74 | Are all the participants truly unbiased about the relative merits of the regimens being studied? |
| cord-015021-pol2qm74 | Before using the model for risk of death in septic patients, is it mandatory to validate it( by calibration, i.e. goodness of fit, and discrin'dnation, i.e., ROC curves) first on a data base using the same definition for sepsis as in the trial and secondly on the placebo group of the trial? |
| cord-015021-pol2qm74 | Can it achives a significant improvement in the septic course, organ dysfunction, and final outcome? |
| cord-015021-pol2qm74 | Conversely, administration of anti- IFN? |
| cord-015021-pol2qm74 | Correlatively the RNI inhibitor MMLA induces in vitro a decrease in the rate of bacterial killing, fxom 78% to 57%, in macrophages triggered with IFN-?+ LPS. |
| cord-015021-pol2qm74 | How can organ dysfunction and/or failure be defined? |
| cord-015021-pol2qm74 | How should we decide which of them should be brought to clinical trial? |
| cord-015021-pol2qm74 | If there is agreement that thin is an appropriate antibiotic protocol, should it not be used in all seriously ill septic patients in the hospital? |
| cord-015021-pol2qm74 | In contrast, GF109203X significantly reduced ICAM-1 expression induced by Interferon- y( IFN-?) |
| cord-015021-pol2qm74 | In fact, the IFN-? and IL-1 induced adhesion of PBMC to cytokine treated HUVEC could be downregulated by the PKC- inhibitor, whereas TNFc~-and LPS- mediated adhesion was not influenced. |
| cord-015021-pol2qm74 | In other words, should we now begin to have clinical trials on specific diseases with causes that are known and can be attacked? |
| cord-015021-pol2qm74 | Interferon-? |
| cord-015021-pol2qm74 | Is like being compared with like-are all the end points and the standards for measuring them clearly defined so that they can not be misunderstood? |
| cord-015021-pol2qm74 | Is there any role for antioxidative therapy in sepsis? |
| cord-015021-pol2qm74 | Is truly informed consent being sought that will satisfy not only the patient's right to choose what happens to him, but also the law of the land? |
| cord-015021-pol2qm74 | MIF secretion also was induced by TNFoc( 1 ng/ ml) and IFN? |
| cord-015021-pol2qm74 | MIF secretion is induced by LPS, TNFc~ and IFN?. |
| cord-015021-pol2qm74 | Macrophages of C57BL/10ScCr mice are incapable of producing interferon-~( IFN~) which we could show to be obligatory for the production of IFN? |
| cord-015021-pol2qm74 | On closer investigation the impaired IFN? |
| cord-015021-pol2qm74 | The IFN? |
| cord-015021-pol2qm74 | The absence of sensitization to LPS in Lps d C57BL/10ScCr mice was identified as being due to their inability to produce interferon-7( IFN?). |
| cord-015021-pol2qm74 | The clinical"take"rate o? cultured epithelial autografts( CEA) has been observed to Increase with transplantation to allodermls, but the reasons for the improved clinical performance have not yet been defined. |
| cord-015021-pol2qm74 | The inability to produce adequate amounts of IL-2, most likely attributable to alterations in the transmission of signals from the cell membrane to the nucleus, results in incomplete proliferative T- cell responses to antigenic stimuli, while a lack of? |
| cord-015021-pol2qm74 | There are reports of nentrophil dysfunction in inflammatory disorders of the skin( 2), Are there dysfunctions concerning the unspecific host defense in SIRS, as well? |
| cord-015021-pol2qm74 | This has not happened, however, and the question is"Why not"? |
| cord-015021-pol2qm74 | This might be due to a preexisting( genetic?) or more likely to an epiphenomenal receptor defect. |
| cord-015021-pol2qm74 | We have investigated the proinflaznmatory oytokine secretion patter~ by PMN in patients following major~hermal or tra~ matic injury and in volunteers fellowinq endotoxemia.? |
| cord-015021-pol2qm74 | What are the definitions? |
| cord-015021-pol2qm74 | What are the issues, then, in 1994, to be dealt with at this symposium and congress? |
| cord-015021-pol2qm74 | What are the mechanisms? |
| cord-015021-pol2qm74 | What is the aplpiieability of study results in typical clinical situations? |
| cord-015021-pol2qm74 | What is the availability of speciftc antibiotics at a participating hospital? |
| cord-015021-pol2qm74 | Will the patient's physicians agree to the protocol choice? |
| cord-015021-pol2qm74 | Will they be helpful in the study and esro of patients? |
| cord-015021-pol2qm74 | Will this contribute to better clinical trials, information basis and better research? |
| cord-015021-pol2qm74 | Will we benefit Oleo from a more precise classification and definition of a non- outjty, a hodgu- podge of human disorders which have charsmeristic.s and manifestations of tissue injury, inflammation and infactian? |
| cord-015021-pol2qm74 | and?-IFN and T- helper-2( Th2) acting principally in inducing antibody formation with a secretion of IL-4, IL-5, IL-10 and TNF-[3 has still to be established within the context of major trauma. |
| cord-015021-pol2qm74 | anti- IFN-?( p<0.05). |
| cord-015021-pol2qm74 | or is it better to use a specific model for each trial? |
| cord-015021-pol2qm74 | ~is s?. |
| cord-014996-p6q0f37c | ( G? M), succinate( S) or ascorbate/ TMPD( A/ T) were used as substrates to test the function of complex I, II and IV, respectively. |
| cord-014996-p6q0f37c | ( Na? |
| cord-014996-p6q0f37c | ** Mean ± SD mean ± standard deviation, min minimum, Max, maximum, PBW 50( men) or 45.5( female)? |
| cord-014996-p6q0f37c | ** p\ 0.01 Tables 1??? |
| cord-014996-p6q0f37c | ** p\ 0.01 Tables 1??? |
| cord-014996-p6q0f37c | ** p\ 0.01 Tables 1??? |
| cord-014996-p6q0f37c | -3.61 to? |
| cord-014996-p6q0f37c | /K? |
| cord-014996-p6q0f37c | /K? |
| cord-014996-p6q0f37c | /K? |
| cord-014996-p6q0f37c | /K? |
| cord-014996-p6q0f37c | /K?-ATPase). |
| cord-014996-p6q0f37c | 17 pts received 3- 5 ml/ kg( 250 ml) HHES( 7.2% NaCl? |
| cord-014996-p6q0f37c | 2.02 L, mean arithmetic error ± SD:? |
| cord-014996-p6q0f37c | A brief history of procalcitonin Biomarkers of sepsis: is procalcitonin ready for prime time? |
| cord-014996-p6q0f37c | A protective role of heterozygousity for the functionally relevant TNFRSF1B? |
| cord-014996-p6q0f37c | A similar pattern was seen in the hepatic? |
| cord-014996-p6q0f37c | After 4 h of ventilation, animals were sacrificed and cardiac function was measured ex vivo in a Langendorff setup and expressed as developed pressure and? |
| cord-014996-p6q0f37c | All files were reviewed to assess the diagnosis of early- onset pneumonia P(?), or not P(-) during the first 5 days of ICU stay. |
| cord-014996-p6q0f37c | CD11c? |
| cord-014996-p6q0f37c | Can they be used as a diagnostic tool in conjunction with procalcitonin in order to direct antimicrobial therapy? |
| cord-014996-p6q0f37c | Characteristics of P(?) |
| cord-014996-p6q0f37c | Data of resistance( R rs), elastance( E rs) and total positive end expiratory pressure( PEEP tot) were obtained by fitting the equation Paw= R rs 9 V 0? |
| cord-014996-p6q0f37c | Developed pressure( p\ 0.01) and? |
| cord-014996-p6q0f37c | Four trials of one hour each were performed at a constant FiO 2 60% during( 1) spontaneous breathing( SB) via a Venturi mask,( 2) CPAP 1,( 3) CPAP? |
| cord-014996-p6q0f37c | Glutamate? |
| cord-014996-p6q0f37c | I am the Best Clinical Educator … are you!? |
| cord-014996-p6q0f37c | In the presence of sevoflurane mRNA level of the a 1-subunit mRNA of Na? |
| cord-014996-p6q0f37c | Levels of TNFa were significantly reduced in the LPS? |
| cord-014996-p6q0f37c | Our aim was to investigate the influence of 1 MAC(= 2.2 vol%) sevoflurane on mRNA and protein levels of ENaC and Na? |
| cord-014996-p6q0f37c | Out the total population, 51.6% of patients, with a median( IQR) pre- operative CRS of 7( 5- 8) underwent a coronary- artery bypass grafting( CABG) surgery, whereas 20.7% of them, with a preoperative median( IQR) NYHA of 3( 2.25- 3) needed a valve replacement( VR) and 16.1% of them combined( CABG? VR) operations; moreover, 11.6% of patients underwent other type of cardiac and aortic surgery. |
| cord-014996-p6q0f37c | P(?) was defined by the presence of a new pulmonary infiltrate on chest radiography, persistent for at least 48 h, associated with either positive quantitative culture of the endotracheal aspirates, either, in case of lack of bacteriological sample, conjunction of purulent sputum and hypoxemia( P/ F\ 200). |
| cord-014996-p6q0f37c | Patients were deemed as having hypoactive delirium if they were DSM positive by the reference rater and had RASS-3 to 0, or having hyperactive delirium if their RASS was between? 1 and? 4. |
| cord-014996-p6q0f37c | Patients were deemed as having hypoactive delirium if they were DSM positive by the reference rater and had RASS-3 to 0, or having hyperactive delirium if their RASS was between? 1 and? 4. |
| cord-014996-p6q0f37c | Previous studies have shown that halothane decreases Na? |
| cord-014996-p6q0f37c | Secondary indices derived from the ICP waveform were analyzed by ICM? software. |
| cord-014996-p6q0f37c | Septic shock( SS) has been defined as sepsis related hypotension despite adequate fluid resuscitation? |
| cord-014996-p6q0f37c | Sequential Kaplan- Meier survival analysis of TNFRSF1B? |
| cord-014996-p6q0f37c | Sequential Kaplan- Meier survival analysis of TNFRSF1B? |
| cord-014996-p6q0f37c | T lymphocytes were distinguished from the other lymphocyte subpopulation as cells labeled with anti- CD3 monoclonal antibody but negative for CD56 staining( CD3? |
| cord-014996-p6q0f37c | The fluid- induced changes in invasive(? 20 ± 36%) and non invasive(? |
| cord-014996-p6q0f37c | The fluid- induced changes in invasive(? 20 ± 36%) and non invasive(? |
| cord-014996-p6q0f37c | V T/ C rs? |
| cord-014996-p6q0f37c | What alters physicians'decisions to admit to the coronary care unit? |
| cord-014996-p6q0f37c | a- subunit Na? |
| cord-014996-p6q0f37c | and 2??? |
| cord-014996-p6q0f37c | and 2??? |
| cord-014996-p6q0f37c | and 2??? |
| cord-014996-p6q0f37c | and CD11c- CD123? |
| cord-014996-p6q0f37c | and-1.26 ± 5.41 kg) and slightly better between BWC and AdjTFB( 0.714 and? 0.18 ± 3.68Kg). |
| cord-014996-p6q0f37c | and-308, LTA? |
| cord-014996-p6q0f37c | and-308, LTA? |